A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Public ClinicalTrials.gov record NCT05277168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Study identification
- NCT ID
- NCT05277168
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- SHR-A1904 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 29, 2022
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2026
- Last update posted
- May 21, 2026
2022 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | Active, not recruiting |
| Comprehensive Hematology Oncology | St. Petersburg | Florida | 33709 | Terminated |
| LSU Health Sciences Center | New Orleans | Louisiana | 70112 | Active, not recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | Terminated |
| Rhode Island Hospital | Providence | Rhode Island | 02905 | Terminated |
| Prisma Health | Greenville | South Carolina | 29605 | Active, not recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05277168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05277168 live on ClinicalTrials.gov.